
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is expected to have a strong year with upcoming catalysts and continued growth, despite potential risks in product launches and macro and litigation concerns. The company's diverse business portfolio, focus on innovation and sustainability, and plans for M&A and restructuring position them for success in the future. A recovery in MedTech and the goal of becoming the top oncology company by 2030 further solidifies JNJ as a strong investment option.
Bears say
Johnson & Johnson is the largest healthcare firm but has divested its consumer business, Kenvue, to focus on innovative medicine and medtech. While restructuring in 2023-24, the company has designated three main therapeutic areas: immunology, oncology, and neurology. However, there has been a decline in some of its core products, resulting in lowered sales estimates and an increasing focus on M&A rather than in-house growth strategies. Additionally, the planned separation of the Orthopaedics business in mid-2027 may pose a risk to JNJ's financials as it accounts for a significant portion of its current revenue.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares